论文部分内容阅读
OBJECTIVE(1) To estimate the value of the subacute MPTP mouse model in aspects of behavioral performance,biochemical changes and pathological abnormalities.(2) To find effective positive drugs.METHODS Male C57 BL/6 mice were injected with MPTP(30 mg·kg~(-1)·d~(-1),ip) for 5 consecutive days.Three days before MPTP injection,the mice were orally administered selegiline(3 mg·kg~(-1)·d~(-1)),pramipexole(3 mg·kg~(-1)·d~(-1)),or medopar(100 mg·kg~(-1)·d~(-1)) for 18 d.Behavioral performance was assessed in the open field test,pole test and rotarod test.Neurotransmitters in the striatum were detected using HPLC.Protein levels were measured by Western blot.Pathological characteristics were examined by immunohistochemistry.Ultrastructure changes were observed by electron microscopy.RESULTS The subacute MPTP treatment did not induce evident motor defects despite severe injuries in the dopaminergic system.Additionally,MPTP significantly increased the α-synuclein levels and the number of astrocytes in the striatum,and destroyed the blood-brain barrier(BBB) in the substantianigra pars compacta.Both selegiline and pramipexole were able to protect the mice against MPTP injuries.CONCLUSION The subacute MPTP mouse model does not show visible motor defects;it is not enough to evaluate the validity of a candidate just based on behavioral examination,much attention should also be paid to the alterations in neurotransmitters,astrocytes,α-synuclein and the BBB.In addition,selegiline or pramipexole is a better choice than medopar as an effective positive control for the subacute MPTP model.
OBJECTIVE (1) To estimate the value of the subacute MPTP mouse model in aspects of behavioral performance, biochemical changes and pathological abnormalities. (2) To find effective positive drugs.METHODS Male C57 BL / 6 mice were injected with MPTP kg -1 d -1, ip) for 5 consecutive days. Th days before MPTP injection, the mice were orally administered selegiline (3 mg · kg -1 · d -1) ), pramipexole (3 mg · kg -1 · d -1), or medopar (100 mg · kg -1 · d -1) for 18 d in the open field test, pole test and rotarod test. Neurotransmitters in the striatum were detected using Western blot. Pathological characteristics were examined by immunohistochemistry. Ultrastructure changes were observed by electron microscopy. RESULTS The subacute MPTP treatment did not induce evident motor injury despite severe injuries in the dopaminergic system. Additionally, MPTP significantly increased α-synuclein levels and the number of astrocytes in the striatum, and destroyed the blood-brain barrier (BBB) in the substantianigra pars compacta.Both selegiline and pramipexole were able to protect the mice against MPTP injuries. CONCLUSION The subacute MPTP mouse model does not show visible motor defects; it is not enough to evaluate the validity of a candidate just based on behavioral examination, more attention should also be paid to the alterations in neurotransmitters, astrocytes, α-synuclein and the BBB.In addition, selegiline or pramipexole is a better choice than medopar as an effective positive control for the subacute MPTP model.